Filing Flows › Insight Molecular Diagnostics (IMDX) › Q1 2025
Insight Molecular Diagnostics (IMDX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Insight Molecular Diagnostics (IMDX) reported revenue of $2.1M for the first quarter 2025 (Q1 2025), up 12-fold from a year earlier and +44% from the quarter before. Operating margin was -318.0%, net loss $6.7M (312.0% of revenue).
Insight Molecular Diagnostics, Q1 2025: revenue $2.1M (12× year over year), operating margin -318.0%, net loss $6.7M, operating cash flow −$5.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.1M | +44% | 12× |
| Operating profit | −$6.8M | — | — |
| Net earnings | −$6.7M | — | — |
| Operating cash flow | −$5.8M | — | — |
What changed
Revenue was $2.1M in Q1 2025, up 1115% year over year and up 44% from the previous quarter.
Gross margin was 62.0%, up 36.4 points from a year earlier. Operating costs exceeded revenue by $6.8M, an operating margin of -318.0%. Operating expenses fell 13% while revenue rose 1115%. The fastest-growing cost line was Sales & marketing (+43%). The quarter ended with a net loss of $6.7M, narrower than the previous quarter's $33.5M loss.
Operating cash flow was −$5.8M. Non-cash charges added back $491K of depreciation and amortization and $473K of share-based compensation. Capital expenditures of $307K exceeded it, leaving free cash flow of −$6.1M.
Questions
What was Insight Molecular Diagnostics' revenue in the first quarter 2025?
Insight Molecular Diagnostics (IMDX) reported revenue of $2.1M for the first quarter 2025 (Q1 2025), up 12-fold from a year earlier and +44% from the quarter before.
Was Insight Molecular Diagnostics profitable in the first quarter 2025?
Operating loss was $6.8M (-318.0% of revenue) and net loss $6.7M.